Patent Analysis
🇺🇸 FDAExpert commentary and market intelligence for pharma strategy teams
Showing 1–3 of 3 articles
Earlier
Critical impact AnalysisJun 5, 2026
STAT Supreme Court backs generic drugmaker in 'skinny labeling' case: Implications for pharma BD and investors
Supreme Court · 6 min
Dr. Sarah MitchellHigh impact AnalysisJun 5, 2026
Daraxonrasib Pancreatic Cancer: What RevMed’s Breakthrough Means for Patients and Pharma
pancreatic cancer · 6 min
Dr. Sarah MitchellHigh impact AnalysisMay 18, 2026
How AI Search is Transforming Pharma Marketing
3 min
Dr. Sarah MitchellExplore intelligence